alluvi-retatrutide798901 - Profile

About me

Profile

Alluvi, previously BI 4744, presents a notable development in weight loss therapy. This dual agonist targeting both GLP-1 and GIP targets demonstrates remarkable efficacy in patient trials,

https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/